Table 3. Treatment administered to study participants by breast cancer type, n (%).

CDK4/6-i: CDK4/6 inhibitors; EC: epirubicin and cyclophosphamide; HT: hormone therapy; RT: radiotherapy; SLNB: selective lymph node biopsy; TN: triple-negative.

Variables	Overall (n = 17)	Luminal (n = 9)	HER2 (n = 6)	TN (n = 2)
Initial systemic treatment
EC + Taxanes	4 (24)	3 (33)	0 (0)	1 (50)
EC + Taxanes + Carboplatin	1 (6)	0 (0)	0 (0)	1 (50)
EC + Taxanes + Anti-HER2	2 (12)	0 (0)	2 (33)	0 (0)
Taxanes + Anti-HER2	4 (24)	0 (0)	4 (67)	0 (0)
HT	1 (6)	1 (11)	0 (0)	0 (0)
HT + CDK4/6-i	5 (29)	5 (56)	0 (0)	0 (0)
Local ablative treatment
Primary
Tumourectomy	2 (12)	1 (11)	1 (17)	0 (0)
Tumourectomy + SLNB	2 (12)	1 (11)	1 (17)	0 (0)
Tumourectomy + Lymphadenectomy	3 (18)	1 (11)	1 (17)	1 (50)
Mastectomy + SLNB	1 (6)	1 (11)	0 (0)	0 (0)
Mastectomy + Lymphadenectomy	7 (41)	4 (44)	2 (33)	1 (50)
RT	2 (12)	1 (11)	1 (17)	0 (0)
Metastasis
None	9 (53)	4 (44)	5 (83)	0 (0)
RT bone M1	5 (29)	5 (56)	0 (0)	0 (0)
RT nodal M1	2 (12)	0 (0)	1 (17)	1 (50)
RT nodal and bone M1	1 (6)	0 (0)	0 (0)	1 (50)
Adjuvant treatment
RT	6 (35)	3 (33)	1 (17)	2 (100)
RT + Anti-HER2	1 (6)	0 (0)	1 (17)	0 (0)
RT + HT	2 (12)	2 (22)	0 (0)	0 (0)
HT	2 (12)	1 (11)	1 (17)	0 (0)
RT + Anti-HER2 + HT	1 (6)	0 (0)	1 (17)	0 (0)
None	5 (29)	3 (33)	2 (33)	0 (0)